|Bid||17.21 x 2900|
|Ask||17.62 x 1800|
|Day's range||17.39 - 19.10|
|52-week range||12.90 - 39.12|
|Beta (5Y monthly)||0.78|
|PE ratio (TTM)||N/A|
|Earnings date||23 Feb 2022 - 28 Feb 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||35.19|
Over the past year, shares of Beam Therapeutics (NASDAQ: BEAM) have soared over 174% higher. This is the firm founded and still run by Cathie Wood, one of the world's most famous investors. Beam Therapeutics is pioneering the use of a new base editing technique in the development of new gene therapies.
Allogene (ALLO) misses earnings estimates for the third quarter. However, the stock rises in after-market trading.
Hello, thank you for standing by, and welcome to Allogene Therapeutics Third Quarter 2021 Conference Call. After the market closed today, Allogene issued a press release that provides a corporate update and financial results for Q3 2021. Joining me on the call today are Dr. David Chang, President and Chief Executive Officer; Dr. Rafael Amado, Executive Vice President of Research and Development and Chief Medical Officer; and Dr. Eric Schmidt, Chief Financial Officer.